Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
Authors
Keywords
-
Journal
Science Advances
Volume 8, Issue 20, Pages -
Publisher
American Association for the Advancement of Science (AAAS)
Online
2022-05-21
DOI
10.1126/sciadv.abk2746
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade
- (2021) Julia Boshuizen et al. CANCER RESEARCH
- Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
- (2021) Enrique J. Arenas et al. Nature Communications
- ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small lung cancer
- (2020) Naoko Okura et al. CLINICAL CANCER RESEARCH
- Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
- (2020) Fara Brasó-Maristany et al. Nature Communications
- ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
- (2020) Gaia Griguolo et al. Cancers
- FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease
- (2020) Susana Garcia-Recio et al. JOURNAL OF CLINICAL INVESTIGATION
- Axl and Mertk receptors cooperate to promote breast cancer progression by combined oncogenic signaling and evasion of host anti-tumor immunity
- (2020) Viralkumar Davra et al. CANCER RESEARCH
- TP-0903 is active in models of drug-resistant acute myeloid leukemia
- (2020) Jae Yoon Jeon et al. JCI Insight
- AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
- (2019) Hirokazu Taniguchi et al. Nature Communications
- HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade
- (2019) Aleix Prat et al. JNCI-Journal of the National Cancer Institute
- AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
- (2019) Donghwa Kim et al. Cell Death & Disease
- AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
- (2019) Stéphane Terry et al. Cancer Immunology Research
- A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers
- (2018) Jing Wei et al. CELLULAR IMMUNOLOGY
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
- (2018) Julia Boshuizen et al. NATURE MEDICINE
- The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
- (2018) Marie-Anne Goyette et al. Cell Reports
- Elevated WBP2 expression in HER2-positive breast cancers correlates with sensitivity to trastuzumab-based neo-adjuvant therapy:A Retrospective and Multicentric Study
- (2018) Shin-Ae Kang et al. CLINICAL CANCER RESEARCH
- New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
- (2018) Anushka Dongre et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
- (2017) Antonio Llombart-Cussac et al. LANCET ONCOLOGY
- Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
- (2017) Marie Schoumacher et al. Current Oncology Reports
- Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
- (2016) M. Scaltriti et al. CLINICAL CANCER RESEARCH
- Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis
- (2016) Wilhem Leconet et al. CLINICAL CANCER RESEARCH
- The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
- (2016) J. Antony et al. Science Signaling
- Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
- (2016) M. A. Miller et al. Cancer Discovery
- Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling
- (2016) Cun Wang et al. Theranostics
- The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
- (2016) J. Antony et al. Science Signaling
- AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
- (2015) Moshe Elkabets et al. CANCER CELL
- Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
- (2015) I-K Park et al. LEUKEMIA
- Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
- (2015) Rocio Vicario et al. PLoS One
- Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization
- (2015) Yaiza del Pozo Martin et al. Cell Reports
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- (2014) Judith Müller et al. Nature Communications
- Molecular Mechanism of 17-Allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL Receptor Tyrosine Kinase Degradation
- (2013) Gnana Prakasam Krishnamoorthy et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Vimentin as a poor prognostic factor for triple-negative breast cancer
- (2013) Nami Yamashita et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival
- (2013) Smita Salian-Mehta et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells
- (2013) M K Asiedu et al. ONCOGENE
- The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
- (2013) A. S. Meyer et al. Science Signaling
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- Axl is essential for VEGF-A-dependent activation of PI3K/Akt
- (2012) Guo-Xiang Ruan et al. EMBO JOURNAL
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- (2011) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer
- (2010) Toru Mukohara CANCER SCIENCE
- Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity
- (2010) A. K. Keating et al. MOLECULAR CANCER THERAPEUTICS
- Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer
- (2010) K Vuoriluoto et al. ONCOGENE
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
- (2009) Balazs Györffy et al. BREAST CANCER RESEARCH AND TREATMENT
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- Epithelial-Mesenchymal Transitions in development and disease: old views and new perspectives
- (2009) M. Angela Nieto INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
- (2009) C. Gjerdrum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now